The antiserum was produced against synthesized peptide derived from human VEGFR1 around the phosphorylation site of Tyr1048. AA range:1016-1065

Phospho-Flt-1 (Y1048) Polyclonal Antibody detects endogenous levels of Flt-1 protein only when phosphorylated at Y1048.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):DIyKN

FLT1

Vascular endothelial growth factor receptor 1

FLT1 ;
FLT ;
FRT ;
VEGFR1 ;
Vascular endothelial growth factor receptor 1 ;
VEGFR-1 ;
Fms-like tyrosine kinase 1 ;
FLT-1 ;
Tyrosine-protein kinase FRT ;
Tyrosine-protein kinase receptor FLT ;
FLT ;
Vascular permeability factor receptor

This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig) -like domains , a transmembrane segment , and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A , VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells , placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened , soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq , May 2009] ,

Alternative products:Additional isoforms seem to exist ,Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. ,Function:Receptor for VEGF , VEGFB and PGF. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. Isoform SFlt1 may have an inhibitory role in angiogenesis. ,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. ,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. ,similarity:Contains 1 protein kinase domain. ,similarity:Contains 7 Ig-like C2-type (immunoglobulin-like) domains. ,subunit:Interacts in vitro with various phosphotyrosine-binding proteins , including PLC-gammas , PTPN11 , GRB2 , CRK and NCK1. ,tissue specificity:Mostly in normal lung , but also in placenta , liver , kidney , heart and brain tissues. Specifically expressed in most of the vascular endothelial cells , and also expressed in peripheral blood monocytes. It is not expressed in tumor cell lines. Isoform sFlt1 is strongly expressed in placenta. ,

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Endosome. Autophosphorylation promotes ubiquitination and endocytosis.; [Isoform 2]: Secreted .; [Isoform 3]: Secreted.; [Isoform 4]: Secreted.; [Isoform 5]: Cytoplasm .; [Isoform 6]: Cytoplasm .; [Isoform 7]: Cytoplasm .

>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>Calcium signaling pathway ;
>>HIF-1 signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Focal adhesion ;
>>Transcriptional misregulation in cancer ;
>>Rheumatoid arthritis